Oxazolidinones are groups of synthetic antimicrobial agents, which have a novel chemical structure. Their mechanism of antimicrobial mainly bacteriostatic via inhibition of protein synthesis. Oxazolidinones are used in serious cases of bacterial infections. Their spectrum of action against a lot of microbes, which often infect humans vigorously, like penicillin and cephalosporin-resistant Streptococcus pneumonia , methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci . Oxazolidinones chemical structure possesses a ring called oxazolidone, which is characterized by the S configuration of the substituent at C5, the acyl-amino-methyl group connected to C5 and the N-aryl substituent. Some oxazolidinones like linezolid were believed to have a role in COVID-19 treatment. It is also noticed that oxazolidinones have a role in improving clinical status of patients with COVID-19 and in decreasing the risk of mortality caused by co-infections. This review was conducted to discuss the chemistry, mechanism, applications and role of oxazolidinones in the treatment of COVID-19.
Clardy, J., Fischbach, M.A. and Currie, C.R. (2009) The Natural History of Antibiotics. Current Biology, 19, R437-R441. https://doi.org/10.1016/j.cub.2009.04.001
Da Cunha Ribeiro, B., Fonseca, L.P. and Calado, C.R. (2019) Antibiotic Discovery: Where Have We Come from, Where Do We Go? Antibiotics (Basel, Switzerland), 8, Article 45. https://doi.org/10.3390/antibiotics8020045
World Health Organization (2021) Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report.
Ayukekbong, J.A., Ntemgwa, M. and Atabe, A.N. (2017) The Threat of Antimicrobial Resistance in Developing Countries: Causes and Control Strategies. Antimicrobial Resistance & Infection Control, 6, Article No. 47. https://doi.org/10.1186/s13756-017-0208-x
Jampilek, J. (2018) Design and Discovery of New Antibacterial Agents: Advances, Perspectives, Challenges. Current Medicinal Chemistry, 25, 4972-5006. https://doi.org/10.2174/0929867324666170918122633
Cassini, A., Hogberg, L.D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G.S., Colomb-Cotinat, M., Kretzschmar, M.E., Devleesschauwer, B., Cecchini, M. and Ouakrim, D.A. (2019) Attributable Deaths and Disability-Adjusted Life-Years Caused by Infections with Antibiotic-Resistant Bacteria in the EU and the European Economic Area in 2015: A Population-Level Modelling Analysis. The Lancet Infectious Diseases, 19, 56-66. https://doi.org/10.1016/S1473-3099(18)30605-4
Zignol, M., Dean, A.S., Falzon, D., van Gemert, W., Wright, A., van Deun, A., Portaels, F., Laszlo, A., Espinal, M.A., Pablos-Méndez, A. and Bloom, A. (2016) Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance. New England Journal of Medicine, 375, 1081-1089. https://doi.org/10.1056/NEJMsr1512438
Jiang, J., Hou, Y., Duan, M., Wang, B., Wu, Y., Ding, X. and Zhao, Y. (2021) Design, Synthesis and Antibacterial Evaluation of Novel Oxazolidinone Derivatives Nitrogen-Containing Fused Heterocyclic Moiety. Bioorganic & Medicinal Chemistry Letters, 32, Article ID: 127660. https://doi.org/10.1016/j.bmcl.2020.127660
Shinabarger, D. (1999) Mechanism of Action of the Oxazolidinone Antibacterial Agents. Expert Opinion on Investigational Drugs, 8, 1195-1202. https://doi.org/10.1517/13543784.8.8.1195
Schlünzen, F., et al. (2001) Structural Basis for the Interaction of Antibiotics with the Peptidyl Transferase Centre in Eubacteria. Nature, 413, 814-821. https://doi.org/10.1038/35101544
Bozdogan, B. and Appelbaum, P.C. (2004) Oxazolidinones: Activity, Mode of Action, and Mechanism of Resistance. International Journal of Antimicrobial Agents, 23, 113-119. https://doi.org/10.1016/j.ijantimicag.2003.11.003
Dorn, C., Schießer, S., Wulkersdorfer, B., Hitzenbichler, F., Kees, M.G. and Zeitlinger, M. (2020) Determination of Free Clindamycin, Flucloxacillin or Tedizolid in Plasma: Pay Attention to Physiological Conditions when Using Ultrafiltration. Biomedical Chromatography, 34, e4820. https://doi.org/10.1002/bmc.4820
Hoagland, D.T., Liu, J., Lee, R.B. and Lee, R.E. (2016) New Agents for the Treatment of Drug-Resistant Mycobacterium tuberculosis. Advanced Drug Delivery Reviews, 102, 55-72. https://doi.org/10.1016/j.addr.2016.04.026
Brenciani, A., Morroni, G., Schwarz, S. and Giovanetti, E. (2022) Oxazolidinones: Mechanisms of Resistance and Mobile Genetic Elements Involved. Journal of Antimicrobial Chemotherapy, 77, 2596-2621. https://doi.org/10.1093/jac/dkac263
Duployez, C., Le Guern, R., Tinez, C., Lejeune, A.L., Robriquet, L., Six, S., Loiez, C. and Wallet, F. (2020) Panton-Valentine Leukocidin-Secreting Staphylococcus Aureus Pneumonia Complicating COVID-19. Emerging Infectious Diseases, 26, Article 1939. https://doi.org/10.3201/eid2608.201413
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. New England Journal of Medicine, 382, 1199-1207. https://doi.org/10.1056/NEJMoa2001316
Zhao, S.X., Wang, C.J., Lu, Y.M., Zhang, X., Wu, S.Y. and Mao, H. (2022) Synthesis and SARS-CoV-2 3CL Protease Inhibitory Effects of Oxazolidinone Derivatives. Journal of the Brazilian Chemical Society, 33, 1134-1143. https://doi.org/10.21577/0103-5053.20220033
Moghadam, V.D. Momenimovahed, Z., Khodadadi, J. and Ghorbani, M. (2021) Linezolid a Potential Treatment for COVID-19 Coinfections. Brazilian Journal of Anesthesiology, 71, 198. https://doi.org/10.1016/j.bjane.2020.12.019
Ang, W., Ye, W., Sang, Z., Liu, Y., Yang, T., Deng, Y., Luo, Y. and Wei, Y. (2014) Discovery of Novel Bis-Oxazolidinone Compounds as Potential Potent and Selective Antitubercular Agents. Bioorganic & Medicinal Chemistry Letters, 24, 1496-1501. https://doi.org/10.1016/j.bmcl.2014.02.025
Shinabarger, D.L., Marotti, K.R., Murray, R.W., Lin, A.H., Melchior, E.P., Swaney, S.M., Dunyak, D.S., Demyan, W.F. and Buysse, J.M. (1997) Mechanism of Action of Oxazolidinones: Effects of Linezolid and Eperezolid on Translation Reactions. Antimicrobial Agents and Chemotherapy, 41, 2132-2136. https://doi.org/10.1128/AAC.41.10.2132
Lin, A.H., Murray, R.W., Vidmar, T.J. and Marotti, K.R. (1997) The Oxazolidinone Eperezolid Binds to the 50S Ribosomal Subunit and Competes with Binding of Chloramphenicol and Lincomycin. Antimicrobial Agents and Chemotherapy, 41, 2127-2131. https://doi.org/10.1128/AAC.41.10.2127
Samaha, R.R., Green, R. and Noller, H.F. (1995) A Base Pair between tRNA and 23S rRNA in the Peptidyl Transferase Centre of the Ribosome. Nature, 377, 309-314. https://doi.org/10.1038/377309a0
Cundliffe, E. and McQuillen, K. (1967) Bacterial Protein Synthesis: The Effects of Antibiotics. Journal of Molecular Biology, 30, 137-146. https://doi.org/10.1016/0022-2836(67)90249-5
Matassova, N.B., Rodnina, M.V., Endermann, R., Kroll, H.P., Pleiss, U., Wild, H. and Wintermeyer, W. (1999) Ribosomal RNA Is the Target for Oxazolidinones, a Novel Class of Translational Inhibitors. RNA, 5, 939-946. https://doi.org/10.1017/S1355838299990210
Swaney, S.M., Aoki, H., Ganoza, M.C. and Shinabarger, D.L. (1998) The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria. Antimicrobial Agents and Chemotherapy, 42, 3251-3255. https://doi.org/10.1128/AAC.42.12.3251
Murray, R.W., Schaadt, R.D., Zurenko, G.E. and Marotti, K.R. (1998) Ribosomes from an Oxazolidinone-Resistant Mutant Confer Resistance to Eperezolid in a Staphylococcus Aureus Cell-Free Transcription-Translation Assay. Antimicrobial Agents and Chemotherapy, 42, 947-950. https://doi.org/10.1128/AAC.42.4.947
Zurenko, G.E., Yagi, B.H., Schaadt, R.D., Allison, J.W., Kilburn, J.O., Glickman, S.E., Hutchinson, D.K., Barbachyn, M.R. and Brickner, S.J. (1996) In Vitro Activities of U-100592 and U-100766, Novel Oxazolidinone Antibacterial Agents. Antimicrobial Agents and Chemotherapy, 40, 839-845. https://doi.org/10.1128/AAC.40.4.839
Vilbrun, S.C., Mathurin, L., Pape, J.W., Fitzgerald, D. and Walsh, K.F. (2020) Case Report: Multidrug-Resistant Tuberculosis and COVID-19 Coinfection in Port-au-Prince, Haiti. The American Journal of Tropical Medicine and Hygiene, 103, 1986-1988. https://doi.org/10.4269/ajtmh.20-0851
Bertram, S., Heurich, A., Lavender, H., Gierer, S., Danisch, S., Perin, P., Lucas, J.M., Nelson, P.S., Pohlmann, S. and Soilleux, E.J. (2012) Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts. PLOS ONE, 7, e35876. https://doi.org/10.1371/journal.pone.0035876
Huang, Y., Yang, C., Xu, X.F., Xu, W. and Liu, S.W. (2020) Structural and Functional Properties of SARS-CoV-2 Spike Protein: Potential Antivirus Drug Development for COVID-19. Acta Pharmacologica Sinica, 41, 1141-1149. https://doi.org/10.1038/s41401-020-0485-4
Brufsky, A. (2020) Distinct Viral Clades of SARS-CoV-2: Implications for Modeling of Viral Spread. Journal of Medical Virology, 92, Article 1386. https://doi.org/10.1002/jmv.25902
Fehr, A.R., Perlman, S., Maier, H.J., Bickerton, E. and Britton, P. (2015) An Overview of Their Replication and Pathogenesis. In: Maier, H., Bickerton, E. and Britton, P., Eds., Genomic Organization. Methods in Molecular Biology, Humana Press, New York, 1-23. https://doi.org/10.1007/978-1-4939-2438-7_1
Morgon, N.H., Grandini, G.S., Yoguim, M.I., Porto, C.M., Santana, L.C., Biswas, S. and de Souza, A.R. (2021) Potential Activity of Linezolid against SARS-CoV-2 Using Electronic and Molecular Docking Study. Journal of Molecular Modeling, 27, Article No. 222. https://doi.org/10.1007/s00894-021-04828-8
Gal-Mor, O., Boyle, E.C. and Grassl, G.A. (2014) Same Species, Different Diseases: How and Why Typhoidal and Non-Typhoidal Salmonella Enterica Serovars Differ. Frontiers in Microbiology, 5, Article 391. https://doi.org/10.3389/fmicb.2014.00391
Han, P., Li, L., Liu, S., Wang, Q., Zhang, D., Xu, Z., Han, P., Li, X., Peng, Q., Su, C., Huang, B., Li, D., Zhang, R., Tian, M., Fu, L., Gao, Y., Zhao, X., Liu, K., Qi, J., Gao, G.F. and Wang, P. (2022) Receptor Binding and Complex Structures of Human ACE2 to Spike RBD from Omicron and Delta SARS-CoV-2. Cell, 185, 630-640. https://doi.org/10.1016/j.cell.2022.01.001
Dai, W.H., Zhang, B., Jiang, X.M., Su, H.X., Li, J., Zhao, Y., Xie, X., et al. (2020) Structure-Based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science, 368, 1331-1335. https://doi.org/10.1126/science.abb4489
Yang, K.S., Ma, X.R., Ma, Y., Alugubelli, Y.R., Scott, D.A., Vatansever, E.C., et al. (2021) A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors. ChemMedChem, 16, 942-948. https://doi.org/10.1002/cmdc.202000924
Shimamoto, Y., Hattori, Y., Kobayashi, K., Teruya, K., Sanjoh, A., Nakagawa, A., Yamashita, E. and Akaji, K. (2015) Fused-Ring Structure of Decahydroisoquinolin as a Novel Scaffold for SARS 3CL Protease Inhibitors. Bioorganic & Medicinal Chemistry, 23, 876-890. https://doi.org/10.1016/j.bmc.2014.12.028
Kumar, V., Tan, K.P., Wang, Y.M., Lin, S.W. and Liang, P.H. (2016) Identification, Synthesis and Evaluation of SARS-CoV and MERS-CoV 3C-Like Protease Inhibitors. Bioorganic & Medicinal Chemistry, 24, 3035-3042. https://doi.org/10.1016/j.bmc.2016.05.013
Deshmukh, M.S. and Jain, N. (2017) Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure. ACS Medicinal Chemistry Letters, 8, 1153-1158. https://doi.org/10.1021/acsmedchemlett.7b00263
Liu, C., Luo, C., Hao, L., Wu, Q., Xie, H., Zhao, S., Hao, C., Zhao, D. and Cheng, M. (2016) Design, Synthesis and Biological Evaluation of Novel Cholesteryl Ester Transfer Protein Inhibitors Bearing a Cycloalkene Scaffold. European Journal of Medicinal Chemistry, 123, 419-430. https://doi.org/10.1016/j.ejmech.2016.07.065
Crowe-McAuliffe, C. and Wilson, D.N. (2022) Putting the Antibiotics Chloramphenicol and Linezolid into Context. Nature Structural & Molecular Biology, 29, 79-81. https://doi.org/10.1038/s41594-022-00725-7
Zhanel, G.G., Shroeder, C., Vercaigne, L., Gin, A.S., Embil, J. and Hoban, D.J. (2001) A Critical Review of Oxazolidinones: An Alternative or Replacement for Glycopeptides and Streptogramins? Canadian Journal of Infectious Diseases and Medical Microbiology, 12, Article ID: 260651. https://doi.org/10.1155/2001/260651
Barbachyn, M.R. and Ford, C.W. (2003) Oxazolidinone Structure-Activity Relationships Leading to Linezolid. Angewandte Chemie International Edition, 42, 2010-2023. https://doi.org/10.1002/anie.200200528
Mukhtar, T.A. and Wright, G.D. (2005) Streptogramins, Oxazolidinones, and Other Inhibitors of Bacterial Protein Synthesis. Chemical Reviews, 105, 529-542. https://doi.org/10.1021/cr030110z
Brickner, S.J., Hutchinson, D.K., Barbachyn, M.R., Manninen, P.R., Ulanowicz, D.A., Garmon, S.A., Grega, K.C., Hendges, S.K., Toops, D.S., Ford, C.W. and Zurenko, G.E. (1996) Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections. Journal of Medicinal Chemistry, 39, 673-679. https://doi.org/10.1021/jm9509556
Chellat, M.F., Raguz, L. and Riedl, R. (2016) Targeting Antibiotic Resistance. Angewandte Chemie International Edition, 55, 6600-6626. https://doi.org/10.1002/anie.201506818
Ippolito, J.A., Kanyo, Z.F., Wang, D., Franceschi, F.J., Moore, P.B., Steitz, T.A. and Duffy, E.M. (2008) Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit. Journal of Medicinal Chemistry, 51, 3353-3356. https://doi.org/10.1021/jm800379d
Wilson, D.N., Schluenzen, F., Harms, J.M., Starosta, A.L., Connell, S.R. and Fucini, P. (2008) The Oxazolidinone Antibiotics Perturb the Ribosomal Peptidyl-Transferase Center and Effect tRNA Positioning. Proceedings of the National Academy of Sciences of the United States of America, 105, 13339-13344. https://doi.org/10.1073/pnas.0804276105
Fines, M. and Leclercq, R. (2000) Activity of Linezolid against Gram-Positive Cocci Possessing Genes Conferring Resistance to Protein Synthesis Inhibitors. Journal of Antimicrobial Chemotherapy, 45, 797-802. https://doi.org/10.1093/jac/45.6.797
Barbachyn, M.R., Brickner, S.J., Gadwood, R.C., Garmon, S.A., Grega, K.C., Hutchinson, D.K., et al. (1998) Design, Synthesis, and Evaluation of Novel Oxazolidinone Antibacterial Agents Active against Multidrug-Resistant Bacteria. In: Rosen, B.P. and Mobashery, S., Eds., Resolving the Antibiotic Paradox, Springer, Boston, MA, 219-238. https://doi.org/10.1007/978-1-4615-4897-3_12
Stevens, D.L., Smith, L.G., Bruss, J.B., McConnell-Martin, M.A., Duvall, S.E., Todd, W.M. and Hafkin, B. (2000) Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections. Antimicrobial Agents and Chemotherapy, 44, 3408-3413. https://doi.org/10.1128/AAC.44.12.3408-3413.2000
Stevens, D.L., Herr, D., Lampiris, H., Hunt, J.L., Batts, D.H. and Hafkin, B. (2002) Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections. Clinical Infectious Diseases, 34, 1481-1490. https://doi.org/10.1086/340353
Bode, C., Muenster, S., Diedrich, B., Jahnert, S., Weisheit, C., Steinhagen, F., et al. (2015) Linezolid, Vancomycin and Daptomycin Modulate Cytokine Production, Toll-Like Receptors and Phagocytosis in a Human in Vitro Model of Sepsis. The Journal of Antibiotics (Tokyo), 68, 485-490. https://doi.org/10.1038/ja.2015.18
Fan, L., Liu, H., Li, N., Liu, C., Gu, Y., Liu, Y. and Chen, Y. (2021) Medical Treatment of 55 Patients with COVID-19 from Seven Cities in Northeast China Who Fully Recovered: A Single-Center, Retrospective, Observational Study. Medicine (Baltimore), 100, e23923. https://doi.org/10.1097/MD.0000000000023923
Alegre-González, D., Herrera, S., Bernal, J., Soriano, A. and Bodro, M.(2021) Disseminated Cryptococcus Neoformans Infection Associated to COVID-19. Medical Mycology Case Reports, 34, 35-37. https://doi.org/10.1016/j.mmcr.2021.10.001